Opus Genetics, Inc.
IRD
$0.865
$0.00430.50%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -42.30% | -85.35% | -63.67% | -54.30% | -52.20% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -42.30% | -85.35% | -63.67% | -54.30% | -52.20% |
| Cost of Revenue | 56.16% | 45.57% | 5.65% | -14.74% | -3.89% |
| Gross Profit | -300.88% | -122.65% | -89.44% | -77.03% | -79.40% |
| SG&A Expenses | 52.43% | 32.04% | 28.55% | 83.47% | 64.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 52.19% | 34.56% | 16.25% | 35.46% | 36.94% |
| Operating Income | -222.58% | -201.37% | -183.07% | -165.26% | -157.96% |
| Income Before Tax | -476.82% | -193.52% | -174.28% | -159.39% | -154.79% |
| Income Tax Expenses | -- | -100.61% | -96.19% | -96.19% | -96.19% |
| Earnings from Continuing Operations | -476.13% | -194.58% | -175.60% | -160.46% | -155.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -476.13% | -194.58% | -175.60% | -160.46% | -155.83% |
| EBIT | -222.58% | -201.37% | -183.07% | -165.26% | -157.96% |
| EBITDA | -222.70% | -201.33% | -183.01% | -165.21% | -157.91% |
| EPS Basic | -340.15% | -178.92% | -160.17% | -154.00% | -157.21% |
| Normalized Basic EPS | -141.61% | -177.79% | -158.76% | -152.67% | -155.35% |
| EPS Diluted | -331.92% | -182.45% | -164.60% | -158.16% | -161.97% |
| Normalized Diluted EPS | -135.88% | -181.44% | -163.54% | -157.17% | -160.43% |
| Average Basic Shares Outstanding | 23.76% | 18.22% | 13.92% | 10.00% | 8.33% |
| Average Diluted Shares Outstanding | 22.40% | 15.97% | 14.15% | 10.27% | 8.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |